Frontier Pharma: Womens Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline
- GBI Research
- February 2018
- 86 pages
The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.
Despite this, the women’s health market is relatively small. This reflects diagnostic barriers and high levels of non-treatment for women’s health disorders, as well as high levels of genericization and relatively limited innovation within recent decades.
Consequently, there is strong rationale for continued R&D investment in women’s health therapeutics due to high levels of unmet need across many indications.
This report assesses first-in-class innovation across the women’s health therapy area, with a particular focus on three key indications: endometriosis, polycystic ovarian syndrome (PCOS) and cervical intraepithelial neoplasia (CIN).
- Many women’s health disorders are highly prevalent. How do epidemiology trends vary for endometriosis, PCOS and CIN?
- Innovation within women’s health has been relatively limited over recent decades. What are the most prominent unmet needs across this therapy area?
- There are 261 pipeline programs in active development for women’s health. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?
- Although the first-in-class pipeline is relatively modest in size it is considerably diverse with eight distinct molecular target classes represented. Which first-in-class targets have been identified as most promising for women’s health conditions?
- Over 200 licensing deals relating to women’s health have been completed since 2006. Do women’s health products typically attract high deal values? Which first-in-class products have prior deal involvement?
Reasons to buy
- Understand the current clinical and commercial landscape. This includes a comprehensive study of symptoms, epidemiology, etiology, pathophysiology, co-morbidities and complications, diagnosis and treatment options.
- Visualize the composition of the women’s health market in terms of dominant molecule types and molecular targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the women’s health pipeline and stratify by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
- Recognize commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals, and identifying women’s health therapies that have not yet been involved in deals and may offer potential investment opportunities.
Have query on this report?Make an Enquiry
Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Executive Summary 6
2.1 Expanding Pipeline Has Potential to Address Unmet Needs of Large Prevalence Population 6
2.2 First-in-Class Innovation Concentrated Across Endometriosis, Polycystic Ovarian Syndrome and Cervical Intraepithelial Neoplasia 6
2.3 Despite High Licensing Deal Activity, Most First-in-Class Products Have No Prior Deal Involvement 6
3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic Products 8
3.2 Diversification of Molecular Targets 8
3.3 Innovative First-in-Class Product Developments Remain Attractive 8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 9
3.5 Sustained Innovation in Women’s Health 9
3.6 GBI Research Report Guidance 10
4 Clinical and Commercial Landscape 11
4.1 Therapy Area Overview 11
4.2 Disease Overview and Symptoms 11
4.2.1 Endometriosis 11
4.2.2 Polycystic Ovarian Syndrome 12
4.2.3 Cervical Intraepithelial Neoplasia 12
4.3 Diagnosis 13
4.3.1 Endometriosis 13
4.3.2 Polycystic Ovarian Syndrome 13
4.3.3 Cervical Intraepithelial Neoplasia 14
4.4 Epidemiology and Etiology 14
4.4.1 Endometriosis 14
4.4.2 Polycystic Ovarian Syndrome 15
4.4.3 Cervical Intraepithelial Neoplasia 16
4.5 Pathophysiology 16
4.5.1 Endometriosis 16
4.5.2 Polycystic Ovarian Syndrome 17
4.5.3 Cervical Intraepithelial Neoplasia 18
4.6 Co-morbidities and Complications 18
4.6.1 Endometriosis 18
4.6.2 Polycystic Ovarian Syndrome 19
4.6.3 Cervical Intraepithelial Neoplasia 19
4.7 Treatment 19
4.7.1 Treatment Options 19
4.7.2 Treatment Algorithms 23
4.8 Overview of Marketed Products within Women’s Health 24
5 Pipeline Assessment 26
5.1 Overview 26
5.2 Pipeline by Stage of Development and Molecule Type 26
5.3 Pipeline by Molecular Target 29
5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 32
5.5 First-in-Class Programs Targeting Novel Molecular Targets 33
5.6 Ratio of First-in-Class Products to First-in-Class Targets 35
5.7 List of All Pipeline Products 36
6 Signalling Network, Disease Causation and Innovation Alignment 46
6.1 Complexity of Signaling Networks 46
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 46
6.3 First-in-Class Matrix Assessments 46
Table 1: Women’s Health, Global, Classification of CIN, 2018 12
Table 2: Women’s Health, Global, PCOS Diagnostic Criteria for NIH, Rotterdam and AE-PCOS Classification Systems, 2018 14
Table 3: Women’s Health, Global, Types of Female Contraceptives, 2018 20
Table 4: Women’s Health, Global, Key Details of Prostaglandin E2 Receptor EP4 Subtype (PTGER4), 2018 51
Table 5: Women’s Health, Global, Pipeline Programs Targeting Prostaglandin E2 Receptor EP4 Subtype (PTGER4), 2018 51
Table 6: Women’s Health, Global, Key Details of Patatin-Like Phospholipase Domain Containing Protein 2 (PNPLA2), 2018 52
Table 7: Women’s Health, Global, Women’s Health, Global, Pipeline Programs Patatin-like Phospholipase Domain Containing Protein 2 (PNPLA2), 2018 52
Table 8: Women’s Health, Global, Key Details of Glutamyl Aminopeptidase (ENPEP), 2018 53
Table 9: Women’s Health, Global, Pipeline Programs Targeting Glutamyl Aminopeptidase (ENPEP), 2018 53
Table 10: Women’s Health, Global, Key Details of Prostaglandin E synthase (PTGES), 2018 55
Table 11: Women’s Health, Global, Pipeline Programs Targeting Prostaglandin E synthase (PTGES), 2018 55
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017